Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-31T14:55:48.757Z Has data issue: false hasContentIssue false
  • English
  • Français

High Dose Flupenthixol Decanoate in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

R. G. McCreadie ,
W. L. Flanagan ,
J. McKnight  and
A. Jorgensen
R. G. McCreadie
Affiliation:
Crichton Royal Hospital, Dumfries (Gartnavel Royal Hospital, Glasgow)
J. McKnight
Affiliation:
Gartnavel Royal Hospital, Glasgow G12 0XH
A. Jorgensen
Affiliation:
H. Lundbeck & Co., A/S Copenhagen, Denmark
Get access Rights & Permissions [Opens in a new window]

Summary

In a double-blind trial, female ‘drug-resistant’ chronic schizophrenic in-patients were given high dose or standard dose flupenthixol decanoate for 13 weeks. Plasma flupenthixol levels showed a five-fold interindividual variation, but were consistently higher with the high dose. Analysis of final scores showed no statistically significant differences between groups with regards to mental state, ward behaviour and extrapyramidal side-effects. When compared with pre-trial scores, the extrapyramidal side-effects worsened significantly in the high dose patients and social withdrawal decreased in the standard dose patients. The mental state of a sub-group of patients, possibly drug resistant for pharmacokinetic reasons, improved significantly on the high dose over the 13 weeks.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 135 , Issue 2 , August 1979 , pp. 175 - 179
Copyright
Copyright © Royal College of Psychiatrists, 1979 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Astrup, C., Grimsgard, A., Hebnes, K., Kruse-Jensen, A. & Lid, M. (1974) A study of flupenthixol decanoate and pipotiazine undecyclenate in schizophrenics. Acta Psychiatrica Scandinavica, 50, 481–91.Google Scholar
Bjerke, K., Faurbye, A. & Kirk, L. (1972) Et ars klinisk erfaring med Flupenthixol decanoat 10 per cent (Lu 1705) i hoj dosernig. Norilsk psychiatrisk tiddskrift, 26, 363.Google Scholar
Dencker, S. J., Johansson, R., Lundin, L. & Malm, U. (1978) High doses of fluphenazine enanthate in schizophrenia. Acta Psychiatrica Scandinavica, 57, 405–14.Google Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munos, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.Google Scholar
Gardos, G. & Cole, J. O. (1973) The importance of dosage in anti-psychotic drug administration: a review of dose response studies. Psychopharmacologia, 29, 221–30.Google Scholar
Gottfries, C. G. (1971) Flupenthixol and trifluoperazine: a double blind investigation in the treatment of schizophrenics. British Journal of Psychiatry, 119, 547–8.Google Scholar
Hall, P. & Coleman, J. (1972) Flupenthixol in the treatment of schizophrenia. British Journal of Psychiatry, 120, 241–2.Google Scholar
Hamilton, M., Smith, A. L. G., Lapidus, H. E. & Cadogan, E. P. (1960) A controlled trial of thiopropazate dihydrochloride (Dartalan). chlorpromazine and occupational therapy in chronic schizophrenics. Journal of Mental Science, 106, 40–55.Google Scholar
Jorgensen, A. (1978) A sensitive and specific radioimmunoassay for cis (z)-flupenthixol in human serum. Life Sciences, 23, 1533–42.Google Scholar
McCreadie, R. G., Heykants, J. J. P., Chalmers, A. & Anderson, A. M. (1979) Plasma pimozide profiles in chronic schizophrenics. British Journal of Clinical Pharmacology, In Press.Google Scholar
McCreadie, R. G. & McDonald, I. M. (1977) High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry, 131, 310–16.Google Scholar
McLelland, H. A., Farquharson, R. G., Leyburn, P., Furness, J. A. & Schiff, A. A. (1976) Very high dose fluphenazine decanoate. Archives of General Psychiatry, 33, 1435–9.CrossRefGoogle Scholar
Sakalis, G., Curry, S. H., Mould, G. P. & Lader, M. H. (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clinical Pharmacology and Therapeutics, 13, 931–46.CrossRefGoogle ScholarPubMed
Siegel, S. (1956) Nonparametric Statistics for the Behavioural Sciences. New York: McGraw-Hill.Google Scholar
Wing, J. K. (1961) A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science, 107, 862–75.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.